Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy
- PMID: 25820757
- PMCID: PMC4587995
- DOI: 10.1002/hep.27819
Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy
Abstract
Altered gut microbiome is associated with systemic inflammation and cirrhosis decompensation. However, the correlation of the oral microbiome with inflammation in cirrhosis is unclear. Our aim was to evaluate the oral microbiome in cirrhosis and compare with stool microbiome. Outpatients with cirrhosis (with/without hepatic encephalopathy [HE]) and controls underwent stool/saliva microbiome analysis (for composition and function) and also systemic inflammatory evaluation. Ninety-day liver-related hospitalizations were recorded. Salivary inflammation was studied using T helper 1 cytokines/secretory immunoglobulin A (IgA), histatins and lysozyme in a subsequent group. A total of 102 patients with cirrhosis (43 previous HE) and 32 age-matched controls were included. On principal component analysis (PCA), stool and saliva microbiome clustered far apart, showing differences between sites as a whole. In salivary microbiome, with previous HE, relative abundance of autochthonous families decreased whereas potentially pathogenic ones (Enterobacteriaceae, Enterococcaceae) increased in saliva. Endotoxin-related predicted functions were significantly higher in cirrhotic saliva. In stool microbiome, relative autochthonous taxa abundance reduced in previous HE, along with increased Enterobacteriaceae and Enterococcaceae. Cirrhotic stool microbiota demonstrated a significantly higher correlation with systemic inflammation, compared to saliva microbiota, on correlation networks. Thirty-eight patients were hospitalized within 90 days. Their salivary dysbiosis was significantly worse and predicted this outcome independent of cirrhosis severity. Salivary inflammation was studied in an additional 86 age-matched subjects (43 controls/43 patients with cirrhosis); significantly higher interleukin (IL)-6/IL-1β, secretory IgA, and lower lysozyme, and histatins 1 and 5 were found in patients with cirrhosis, compared to controls.
Conclusions: Dysbiosis, represented by reduction in autochthonous bacteria, is present in both saliva and stool in patients with cirrhosis, compared to controls. Patients with cirrhosis have impaired salivary defenses and worse inflammation. Salivary dysbiosis was greater in patients with cirrhosis who developed 90-day hospitalizations. These findings could represent a global mucosal-immune interface change in cirrhosis.
© 2015 by the American Association for the Study of Liver Diseases.
Figures
Comment in
-
Salivary microbiota-immune profiling in cirrhosis: could this be the noninvasive strategy that will revolutionize prognostication in hepatology?Hepatology. 2015 Oct;62(4):1001-3. doi: 10.1002/hep.27870. Epub 2015 Jun 19. Hepatology. 2015. PMID: 25998053 No abstract available.
-
Reply.Hepatology. 2016 May;63(5):1736-7. doi: 10.1002/hep.27952. Epub 2015 Aug 3. Hepatology. 2016. PMID: 26105621 No abstract available.
-
Oro-hepatic link, endotoxemia, and systemic inflammation: The role of chronic periodontitis.Hepatology. 2016 May;63(5):1736. doi: 10.1002/hep.27953. Epub 2015 Jul 31. Hepatology. 2016. PMID: 26105750 No abstract available.
Similar articles
-
Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.Am J Physiol Gastrointest Liver Physiol. 2012 Sep 15;303(6):G675-85. doi: 10.1152/ajpgi.00152.2012. Epub 2012 Jul 19. Am J Physiol Gastrointest Liver Physiol. 2012. PMID: 22821944 Free PMC article.
-
Altered profile of human gut microbiome is associated with cirrhosis and its complications.J Hepatol. 2014 May;60(5):940-7. doi: 10.1016/j.jhep.2013.12.019. Epub 2013 Dec 25. J Hepatol. 2014. PMID: 24374295 Free PMC article.
-
Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus.Sci Rep. 2015 Dec 22;5:18559. doi: 10.1038/srep18559. Sci Rep. 2015. PMID: 26692421 Free PMC article.
-
The role of microbiota in hepatic encephalopathy.Gut Microbes. 2014 May-Jun;5(3):397-403. doi: 10.4161/gmic.28684. Epub 2014 Apr 1. Gut Microbes. 2014. PMID: 24690956 Free PMC article. Review.
-
Altered Microbiome in Patients With Cirrhosis and Complications.Clin Gastroenterol Hepatol. 2019 Jan;17(2):307-321. doi: 10.1016/j.cgh.2018.08.008. Epub 2018 Aug 9. Clin Gastroenterol Hepatol. 2019. PMID: 30099098 Free PMC article. Review.
Cited by
-
The RIVET RCT: Rifamycin SV MMX improves muscle mass, physical function, and ammonia in cirrhosis and minimal encephalopathy.Hepatol Commun. 2024 Feb 3;8(2):e0384. doi: 10.1097/HC9.0000000000000384. eCollection 2024 Feb 1. Hepatol Commun. 2024. PMID: 38315140 Free PMC article. Clinical Trial.
-
Oral microbiome characteristics in patients with pediatric solid tumor.Front Microbiol. 2024 Jan 5;14:1286522. doi: 10.3389/fmicb.2023.1286522. eCollection 2023. Front Microbiol. 2024. PMID: 38249475 Free PMC article.
-
Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link.J Clin Transl Hepatol. 2023 Dec 28;11(7):1498-1507. doi: 10.14218/JCTH.2023.00069. Epub 2023 Sep 15. J Clin Transl Hepatol. 2023. PMID: 38161503 Free PMC article. Review.
-
Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.Int J Mol Sci. 2023 Nov 19;24(22):16502. doi: 10.3390/ijms242216502. Int J Mol Sci. 2023. PMID: 38003692 Free PMC article. Review.
-
Systematic mining of the human microbiome identifies antimicrobial peptides with diverse activity spectra.Nat Microbiol. 2023 Dec;8(12):2420-2434. doi: 10.1038/s41564-023-01524-6. Epub 2023 Nov 16. Nat Microbiol. 2023. PMID: 37973865
References
-
- Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28:26–42. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous